Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;17(6):564-572.
doi: 10.2174/1570161116666180709095348.

Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?

Panagiotis Anagnostis  1 , Stavroula A Paschou  2 , Niki Katsiki  3 , Dimitrios Krikidis  4 , Irene Lambrinoudaki  5 , Dimitrios G Goulis  1
Affiliations
Review

Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?

Panagiotis Anagnostis et al. Curr Vasc Pharmacol. 2019.

Abstract

Transition to menopause is associated with an increase in cardiovascular disease (CVD) risk, mainly attributed to lipid and glucose metabolism dysregulation, as well as to body fat redistribution, leading to abdominal obesity. Indeed, epidemiological evidence suggests that both early menopause (EM, defined as age at menopause <45 years) and premature ovarian insufficiency (POI, defined as age at menopause <40 years) are associated with 1.5-2-fold increase in CVD risk. Menopausal hormone therapy (MHT) exerts a favorable effect on CVD risk factors (with subtle differences regarding oestrogen dose, route of administration, monotherapy or combination with progestogen and type of progestogen). Concerning CVD morbidity and mortality, most studies have shown a beneficial effect of MHT in women at early menopausal age (<10 years since the final menstrual period) or younger than 60 years. MHT is strongly recommended in women with EM and POI, as these women, if left untreated, are at risk of CVD, osteoporosis, dementia, depression and premature death. MHT has also a favorable benefit/ risk profile in perimenopausal and early postmenopausal women, provided that the patient is not at a high CVD risk (as assessed by 10-year calculation tools). Transdermal oestrogens have a lower risk of thrombosis compared with oral regimens. Concerning progestogens, natural progesterone and dydrogesterone have a neutral effect on CVD risk factors. In any case, the decision for MHT should be individualized, tailored according to the symptoms, patient preference and the risk of CVD, thrombotic episodes and breast cancer.

Keywords: Menopausal hormone therapy; cardiovascular risk; diabetes; dyslipidaemia; menopause; postmenopausal women..

PubMed Disclaimer

Similar articles

  • Menopause-associated risk of cardiovascular disease.
    Anagnostis P, Lambrinoudaki I, Stevenson JC, Goulis DG. Anagnostis P, et al. Endocr Connect. 2022 Apr 22;11(4):e210537. doi: 10.1530/EC-21-0537. Endocr Connect. 2022. PMID: 35258483 Free PMC article. Review.
  • Cardiovascular health and the menopause, metabolic health.
    Anagnostis P, Stevenson JC. Anagnostis P, et al. Best Pract Res Clin Endocrinol Metab. 2024 Jan;38(1):101781. doi: 10.1016/j.beem.2023.101781. Epub 2023 Apr 25. Best Pract Res Clin Endocrinol Metab. 2024. PMID: 37183085 Review.
  • Menopause and diabetes: EMAS clinical guide.
    Slopien R, Wender-Ozegowska E, Rogowicz-Frontczak A, Meczekalski B, Zozulinska-Ziolkiewicz D, Jaremek JD, Cano A, Chedraui P, Goulis DG, Lopes P, Mishra G, Mueck A, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Tuomikoski P, Paschou SA, Anagnostis P, Lambrinoudaki I. Slopien R, et al. Maturitas. 2018 Nov;117:6-10. doi: 10.1016/j.maturitas.2018.08.009. Epub 2018 Aug 23. Maturitas. 2018. PMID: 30314563
  • Menopausal hormone therapy and breast cancer risk.
    Rozenberg S, Di Pietrantonio V, Vandromme J, Gilles C. Rozenberg S, et al. Best Pract Res Clin Endocrinol Metab. 2021 Dec;35(6):101577. doi: 10.1016/j.beem.2021.101577. Epub 2021 Sep 10. Best Pract Res Clin Endocrinol Metab. 2021. PMID: 34535397 Review.
  • Hormone therapy in menopause: An update on cardiovascular disease considerations.
    Hale GE, Shufelt CL. Hale GE, et al. Trends Cardiovasc Med. 2015 Aug;25(6):540-9. doi: 10.1016/j.tcm.2015.01.008. Epub 2015 Feb 12. Trends Cardiovasc Med. 2015. PMID: 26270318 Review.
See all similar articles

Cited by

See all "Cited by" articles

LinkOut - more resources

  NODES
admin 1
INTERN 2
twitter 2